Skip to content

Study · Not a test of the peptide alone · 2012

2 results

Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.

Esposito S, Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P

Drug testing and analysis7 Sept 2012Cited by 31 (Europe PMC)

PMID22962027 (opens in a new tab)DOI10.1002/dta.1402 (opens in a new tab)PepBankPUB-22962027
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, TB-500 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking TB-500.

  1. 01LabNot a test of TB-500 aloneIn vitro (cell-free)Other

    HPLC with high resolution mass spectrometry detected and identified the N-terminal acetylated 17-23 fragment of human thymosin beta 4 (Ac-LKKTETQ) in TB‑500.

    In plain wordsIn lab tests, mass spectrometry found and identified the Ac-LKKTETQ peptide fragment in the TB‑500 product.

    Peptide
    TB-500
    Outcome
    Not applicableIdentification of Ac-LKKTETQ in TB-500
    Study

    n: not reported in source

    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    This work describes the detection and the identification of the N-terminal acetylated 17-23 fragment of human thymosin beta 4 (Ac-LKKTETQ) in TB-500 by means of high-performance liquid chromatography/high resolution mass spectrometry using an Orbitrap Exactive benchtop mass spectrometer.
    1 context sentence
    Title · context
    Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.

    In this study, TB-500 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking TB-500.

  2. 02LabNot a test of TB-500 aloneIn vitro (cell-free)Other

    Ac-LKKTETQ was synthesized by solid-phase peptide synthesis, and a triple-quadrupole mass spectrometry strategy for detection in plasma and urine was suggested.

    In plain wordsIn the lab, Ac-LKKTETQ was made by chemical synthesis, and a test to detect it in plasma and urine was proposed.

    Peptide
    TB-500
    Outcome
    Not applicableSynthesis of Ac-LKKTETQ and plasma and urine detection strategy
    Study

    n: not reported in source

    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    Ac-LKKTETQ was also synthesized by solid-phase peptide synthesis, and an analytical strategy for detection in plasma and urine by high-performance liquid chromatography/low resolution triple-quadrupole mass spectrometry was suggested.
    1 context sentence
    Title · context
    Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.

    In this study, TB-500 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking TB-500.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 5 to 29Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 25 times, first on 13 Oct 2026, 01:52 UTC. The status did not change between them.

    Study results updated

  2. Version 4

    12 Oct 2026, 18:17 UTC

    Study data updated · source update from Europe PMC

  3. Version 3

    9 Oct 2026, 18:17 UTC

    Study results updated

  4. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  5. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.